Amgen's midpoint non-GAAP diluted EPS payout ratio will be 41.9% for this year and will only slightly expand to 43.2% next year, despite the recent 10.2% dividend hike. Even with continued COVID-19 headwinds, the company's year-to-date revenue edged 1.8% higher over the year-ago period and non-GAAP diluted EPS increased 1.1% during that time.